Tag: AGN

Argenica Therapeutics ASX AGN Phase 1 clinical trial stroke roadmap

Argenica Therapeutics to start phase 1 clinical trials early next year

After extensive research and pre-clinical studies, Argenica Therapeutics (ASX: AGN) is gearing up to begin the phase 1 clinical trial for its stroke treatment drug ARG-007 in the first quarter of next...
Argenica Therapeutics ASX AGN Phase 1 clinical trial stroke treatment drug ARG-007 Linear Clinical Research

Argenica Therapeutics commences preparations for phase 1 clinical trial of stroke-treatment drug ARG-007

Biotechnology company Argenica Therapeutics (ASX: AGN) has engaged Perth-based company Linear Clinical Research to initiate preliminary work required for a phase 1 trial into the safety and tolerabili...
Argenica Therapeutics ASX AGN Good Manufacturing Practice GMP stroke therapeutic ARG-007

Argenica Therapeutics produces GMP-grade ARG-007 for prevention of brain tissue death in stroke patients

Newly-listed biotech Argenica Therapeutics (ASX: AGN) has confirmed that two of its manufacturing partners have produced scaled-up, GMP-grade batches of its neuroprotective peptide candidate ARG-007 f...
Argenica Therapeutics ASX AGN stroke

Argenica Therapeutics prepares for clinical trials of novel stroke treatment

Developer of a novel treatment for stroke victims Argenica Therapeutics (ASX: AGN) has made its ASX debut today after a successful $7 million IPO. With Alto Capital acting as the lead manager to th...